학술논문

Efficacy of bone resorption inhibitors (BRI) plus abiraterone acetate plus prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.